{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:43:17Z","timestamp":1791603797629,"version":"4.3.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82274478"],"award-info":[{"award-number":["82274478"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-026-04342-8","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:14:42Z","timestamp":1778480082000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative efficacy and safety of monotherapy and combination pharmacotherapies for idiopathic pulmonary fibrosis: a network meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"26","author":[{"given":"Jitao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xitong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"4342_CR1","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198:e44\u201368. https:\/\/doi.org\/10.1164\/rccm.201807-1255ST.","journal-title":"Am J Respir Crit Care Med"},{"key":"4342_CR2","doi-asserted-by":"publisher","first-page":"e036809","DOI":"10.1136\/bmjopen-2020-036809","volume":"10","author":"B Xie","year":"2020","unstructured":"Xie B, Ren Y, Geng J, He X, Ban C, Wang S, et al. Idiopathic Pulmonary Fibrosis Registry China study (PORTRAY): protocol for a prospective, multicentre registry study. BMJ Open. 2020;10:e036809. https:\/\/doi.org\/10.1136\/bmjopen-2020-036809.","journal-title":"BMJ Open"},{"key":"4342_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1183\/13993003.01653-2015","volume":"48","author":"G Raghu","year":"2016","unstructured":"Raghu G, Chen S-Y, Hou Q, Yeh W-S, Collard HR. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18\u201364 years old. Eur Respir J. 2016;48:179\u201386. https:\/\/doi.org\/10.1183\/13993003.01653-2015.","journal-title":"Eur Respir J"},{"key":"4342_CR4","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.3390\/cells11213379","volume":"11","author":"C-H Yegen","year":"2022","unstructured":"Yegen C-H, Haine L, Da Costa Ferreira K, Marchant D, Bernaudin J-F, Plan\u00e8s C, et al. A New Model of Acute Exacerbation of Experimental Pulmonary Fibrosis in Mice. Cells. 2022;11:3379. https:\/\/doi.org\/10.3390\/cells11213379.","journal-title":"Cells"},{"key":"4342_CR5","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.3390\/cells13242050","volume":"13","author":"N Ouji-Sageshima","year":"2024","unstructured":"Ouji-Sageshima N, Hiyama A, Kumamoto M, Kitabatake M, Hara A, Furukawa R, et al. Adipose-Derived Mesenchymal Stem Cells (ADSCs) Have Anti-Fibrotic Effects on Lung Fibroblasts from Idiopathic Pulmonary Fibrosis (IPF) Patients. Cells. 2024;13:2050. https:\/\/doi.org\/10.3390\/cells13242050.","journal-title":"Cells"},{"key":"4342_CR6","doi-asserted-by":"publisher","first-page":"116282","DOI":"10.1016\/j.biopha.2024.116282","volume":"173","author":"J Ma","year":"2024","unstructured":"Ma J, Li G, Wang H, Mo C. Comprehensive review of potential drugs with anti-pulmonary fibrosis properties. Biomed Pharmacother. 2024;173:116282. https:\/\/doi.org\/10.1016\/j.biopha.2024.116282.","journal-title":"Biomed Pharmacother"},{"key":"4342_CR7","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202503-262OC","author":"Y Fan","year":"2025","unstructured":"Fan Y, Bao H, Pimple P, Olson AL, Nathan SD. Incidence Rate and Prevalence of Idiopathic Pulmonary Fibrosis in the United States 2017\u20132022. Ann Am Thorac Soc. 2025. https:\/\/doi.org\/10.1513\/AnnalsATS.202503-262OC. :AnnalsATS.202503-262OC.","journal-title":"Ann Am Thorac Soc"},{"key":"4342_CR8","doi-asserted-by":"publisher","first-page":"114253","DOI":"10.1016\/j.biopha.2023.114253","volume":"159","author":"C Tao","year":"2023","unstructured":"Tao C, Xian H, Nian-yu Z, Jia-cui S, Dong W, Hui-ping L. C-type lectin Mincle initiates IL-17-mediated inflammation in acute exacerbations of idiopathic pulmonary fibrosis. Biomed Pharmacother. 2023;159:114253. https:\/\/doi.org\/10.1016\/j.biopha.2023.114253.","journal-title":"Biomed Pharmacother"},{"key":"4342_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ajps.2022.04.004","volume":"17","author":"P Lu","year":"2022","unstructured":"Lu P, Li J, Liu C, Yang J, Peng H, Xue Z, et al. Salvianolic acid B dry powder inhaler for the treatment of idiopathic pulmonary fibrosis. Asian J Pharm Sci. 2022;17:447\u201361. https:\/\/doi.org\/10.1016\/j.ajps.2022.04.004.","journal-title":"Asian J Pharm Sci"},{"key":"4342_CR10","doi-asserted-by":"publisher","first-page":"e172058","DOI":"10.1172\/JCI172058","volume":"133","author":"J May","year":"2023","unstructured":"May J, Mitchell JA, Jenkins RG. Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis. J Clin Invest. 2023;133:e172058. https:\/\/doi.org\/10.1172\/JCI172058.","journal-title":"J Clin Invest"},{"key":"4342_CR11","doi-asserted-by":"publisher","first-page":"116298","DOI":"10.1016\/j.biopha.2024.116298","volume":"173","author":"C-W Huang","year":"2024","unstructured":"Huang C-W, Lee S-Y, Du C-X, Wu S-T, Kuo Y-H, Ku H-C. Caffeic acid ethanolamide induces antifibrosis, anti-inflammatory, and antioxidant effects protects against bleomycin-induced pulmonary fibrosis. Biomed Pharmacother. 2024;173:116298. https:\/\/doi.org\/10.1016\/j.biopha.2024.116298.","journal-title":"Biomed Pharmacother"},{"key":"4342_CR12","doi-asserted-by":"publisher","first-page":"5622","DOI":"10.1021\/acs.jmedchem.2c02087","volume":"66","author":"E Armani","year":"2023","unstructured":"Armani E, Rizzi A, Iotti N, Saccani F, Di Lascia MR, Tigli L, et al. Discovery of a Potent, Selective, and Orally Bioavailable Tool Compound for Probing the Role of Lysophosphatidic Acid Type 2 Receptor Antagonists in Fibrotic Disorders. J Med Chem. 2023;66:5622\u201356. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c02087.","journal-title":"J Med Chem"},{"key":"4342_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/cells11010143","volume":"11","author":"K Takehara","year":"2022","unstructured":"Takehara K, Koga Y, Hachisu Y, Utsugi M, Sawada Y, Saito Y, et al. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Cells. 2022;11:143. https:\/\/doi.org\/10.3390\/cells11010143.","journal-title":"Cells"},{"key":"4342_CR14","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jama.2024.8693","volume":"332","author":"G Raghu","year":"2024","unstructured":"Raghu G, Richeldi L, Fern\u00e1ndez P\u00e9rez ER, De Salvo MC, Silva RS, Song JW, et al. Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial. JAMA. 2024;332:380. https:\/\/doi.org\/10.1001\/jama.2024.8693.","journal-title":"JAMA"},{"key":"4342_CR15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1164\/rccm.202310-1907OC","volume":"210","author":"WLLD Mattos","year":"2024","unstructured":"Mattos WLLD, Khalil N, Spencer LG, Bonella F, Folz RJ, Rolf JD, et al. Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2024;210:435\u201343. https:\/\/doi.org\/10.1164\/rccm.202310-1907OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"4342_CR16","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","volume":"392","author":"TM Maher","year":"2025","unstructured":"Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold A-M, Kreuter M, et al. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med. 2025;392:2203\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2503643.","journal-title":"N Engl J Med"},{"key":"4342_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162:777\u201384. https:\/\/doi.org\/10.7326\/M14-2385.","journal-title":"Ann Intern Med"},{"key":"4342_CR18","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.chest.2022.03.044","volume":"162","author":"A Bratt","year":"2022","unstructured":"Bratt A, Williams JM, Liu G, Panda A, Patel PP, Walkoff L, et al. Predicting Usual Interstitial Pneumonia Histopathology From Chest CT Imaging With Deep Learning. Chest. 2022;162:815\u201323. https:\/\/doi.org\/10.1016\/j.chest.2022.03.044.","journal-title":"Chest"},{"key":"4342_CR19","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.3390\/cells11162487","volume":"11","author":"E El Agha","year":"2022","unstructured":"El Agha E, Wygrecka M. State of the Art in Idiopathic Pulmonary Fibrosis. Cells. 2022;11:2487. https:\/\/doi.org\/10.3390\/cells11162487.","journal-title":"Cells"},{"key":"4342_CR20","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1513\/AnnalsATS.202107-897OC","volume":"19","author":"JA Lasky","year":"2022","unstructured":"Lasky JA, Case A, Unterman A, Kreuter M, Scholand MB, Chaudhary S, et al. The Impact of the Envisia Genomic Classifier in the Diagnosis and Management of Patients with Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2022;19:916\u201324. https:\/\/doi.org\/10.1513\/AnnalsATS.202107-897OC.","journal-title":"Ann Am Thorac Soc"},{"key":"4342_CR21","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","volume":"392","author":"L Richeldi","year":"2025","unstructured":"Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, et al. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2025;392:2193\u2013202. https:\/\/doi.org\/10.1056\/NEJMoa2414108.","journal-title":"N Engl J Med"},{"key":"4342_CR22","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"4342_CR23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jclinepi.2022.07.014","volume":"150","author":"L Zeng","year":"2022","unstructured":"Zeng L, Brignardello-Petersen R, Hultcrantz M, Mustafa RA, Murad MH, Iorio A, et al. GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. J Clin Epidemiol. 2022;150:216\u201324. https:\/\/doi.org\/10.1016\/j.jclinepi.2022.07.014.","journal-title":"J Clin Epidemiol"},{"key":"4342_CR24","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, Du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370:2071\u201382. https:\/\/doi.org\/10.1056\/NEJMoa1402584.","journal-title":"N Engl J Med"},{"key":"4342_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/thoraxjnl-2016-209701","volume":"73","author":"L Richeldi","year":"2018","unstructured":"Richeldi L, Kreuter M, Selman M, Crestani B, Kirsten A-M, Wuyts WA, et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax. 2018;73:581\u20133. https:\/\/doi.org\/10.1136\/thoraxjnl-2016-209701.","journal-title":"Thorax"},{"key":"4342_CR26","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1164\/rccm.200906-0964OC","volume":"181","author":"CE Daniels","year":"2010","unstructured":"Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR. Imatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results. Am J Respir Crit Care Med. 2010;181:604\u201310. https:\/\/doi.org\/10.1164\/rccm.200906-0964OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"4342_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1440-1843.2012.02132.x","volume":"17","author":"S Homma","year":"2012","unstructured":"Homma S, Azuma A, Taniguchi H, Ogura T, Mochiduki Y, Sugiyama Y, et al. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology. 2012;17:467\u201377. https:\/\/doi.org\/10.1111\/j.1440-1843.2012.02132.x.","journal-title":"Respirology"},{"key":"4342_CR28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00408-009-9209-8","volume":"188","author":"RM Jackson","year":"2010","unstructured":"Jackson RM, Glassberg MK, Ramos CF, Bejarano PA, Butrous G, G\u00f3mez-Mar\u00edn O. Sildenafil Therapy and Exercise Tolerance in Idiopathic Pulmonary Fibrosis. Lung. 2010;188:115\u201323. https:\/\/doi.org\/10.1007\/s00408-009-9209-8.","journal-title":"Lung"},{"key":"4342_CR29","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King","year":"2014","unstructured":"King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370:2083\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1402582.","journal-title":"N Engl J Med"},{"key":"4342_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1164\/rccm.200705-732OC","volume":"177","author":"TE King","year":"2008","unstructured":"King TE, Behr J, Brown KK, Du Bois RM, Lancaster L, De Andrade JA, et al. BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2008;177:75\u201381. https:\/\/doi.org\/10.1164\/rccm.200705-732OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"4342_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1164\/rccm.201011-1874OC","volume":"184","author":"TE King","year":"2011","unstructured":"King TE, Brown KK, Raghu G, Du Bois RM, Lynch DA, Martinez F, et al. BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2011;184:92\u20139. https:\/\/doi.org\/10.1164\/rccm.201011-1874OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"4342_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/1874306402014010022","volume":"14","author":"L Lancaster","year":"2020","unstructured":"Lancaster L, Goldin J, Trampisch M, Kim GH, Ilowite J, Homik L, et al. Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis. Open Respir Med J. 2020;14:22\u201331. https:\/\/doi.org\/10.2174\/1874306402014010022.","journal-title":"Open Respir Med J"},{"key":"4342_CR33","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S2213-2600(18)30181-4","volume":"6","author":"TM Maher","year":"2018","unstructured":"Maher TM, Van Der Aar EM, Van De Steen O, Allamassey L, Desrivot J, Dupont S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med. 2018;6:627\u201335. https:\/\/doi.org\/10.1016\/S2213-2600(18)30181-4.","journal-title":"Lancet Respir Med"},{"key":"4342_CR34","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S2213-2600(19)30255-3","volume":"7","author":"TM Maher","year":"2019","unstructured":"Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, et al. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respir Med. 2019;7:771\u20139. https:\/\/doi.org\/10.1016\/S2213-2600(19)30255-3.","journal-title":"Lancet Respir Med"},{"key":"4342_CR35","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1401739","volume":"370","author":"The Idiopathic Pulmonary Fibrosis Clinical Research Network","year":"2014","unstructured":"The Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370:2093\u2013101. https:\/\/doi.org\/10.1056\/NEJMoa1401739.","journal-title":"N Engl J Med"},{"key":"4342_CR36","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(11)60405-4.","journal-title":"Lancet"},{"key":"4342_CR37","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1001\/jama.2018.6129","volume":"319","author":"G Raghu","year":"2018","unstructured":"Raghu G, Van Den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, et al. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. JAMA. 2018;319:2299. https:\/\/doi.org\/10.1001\/jama.2018.6129.","journal-title":"JAMA"},{"key":"4342_CR38","doi-asserted-by":"publisher","unstructured":"Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al. Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan. https:\/\/doi.org\/10.7326\/0003-4819-158-9-201305070-00003.","DOI":"10.7326\/0003-4819-158-9-201305070-00003"},{"key":"4342_CR39","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1183\/09031936.00104612","volume":"42","author":"G Raghu","year":"2013","unstructured":"Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J, the MUSIC Study Group. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J. 2013;42:1622\u201332. https:\/\/doi.org\/10.1183\/09031936.00104612.","journal-title":"Eur Respir J"},{"key":"4342_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-2600(16)30421-0","volume":"5","author":"G Raghu","year":"2017","unstructured":"Raghu G, Brown KK, Collard HR, Cottin V, Gibson KF, Kaner RJ, et al. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respir Med. 2017;5:22\u201332. https:\/\/doi.org\/10.1016\/S2213-2600(16)30421-0.","journal-title":"Lancet Respir Med"},{"key":"4342_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S2213-2600(19)30262-0","volume":"8","author":"L Richeldi","year":"2020","unstructured":"Richeldi L, Fern\u00e1ndez P\u00e9rez ER, Costabel U, Albera C, Lederer DJ, Flaherty KR, et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2020;8:25\u201333. https:\/\/doi.org\/10.1016\/S2213-2600(19)30262-0.","journal-title":"Lancet Respir Med"},{"key":"4342_CR42","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1183\/09031936.00005209","volume":"35","author":"H Taniguchi","year":"2010","unstructured":"Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821\u20139. https:\/\/doi.org\/10.1183\/09031936.00005209.","journal-title":"Eur Respir J"},{"key":"4342_CR43","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1183\/13993003.00850-2015","volume":"47","author":"B Van Den Blink","year":"2016","unstructured":"Van Den Blink B, Dillingh MR, Ginns LC, Morrison LD, Moerland M, Wijsenbeek M, et al. Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. Eur Respir J. 2016;47:889\u201397. https:\/\/doi.org\/10.1183\/13993003.00850-2015.","journal-title":"Eur Respir J"},{"key":"4342_CR44","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa1002110","volume":"363","author":"A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis","year":"2010","unstructured":"A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis. N Engl J Med. 2010;363:620\u20138. https:\/\/doi.org\/10.1056\/NEJMoa1002110.","journal-title":"N Engl J Med"},{"key":"4342_CR45","doi-asserted-by":"publisher","first-page":"2000348","DOI":"10.1183\/13993003.00348-2020","volume":"57","author":"S Sakamoto","year":"2021","unstructured":"Sakamoto S, Kataoka K, Kondoh Y, Kato M, Okamoto M, Mukae H, et al. Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial. Eur Respir J. 2021;57:2000348. https:\/\/doi.org\/10.1183\/13993003.00348-2020.","journal-title":"Eur Respir J"},{"key":"4342_CR46","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-2600(16)30044-3","volume":"4","author":"J Behr","year":"2016","unstructured":"Behr J, Bendstrup E, Crestani B, G\u00fcnther A, Olschewski H, Sk\u00f6ld CM, et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2016;4:445\u201353. https:\/\/doi.org\/10.1016\/S2213-2600(16)30044-3.","journal-title":"Lancet Respir Med"},{"key":"4342_CR47","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S2213-2600(21)00354-4","volume":"10","author":"J-M Naccache","year":"2022","unstructured":"Naccache J-M, Jouneau S, Didier M, Borie R, Cachanado M, Bourdin A, et al. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022;10:26\u201334. https:\/\/doi.org\/10.1016\/S2213-2600(21)00354-4.","journal-title":"Lancet Respir Med"},{"key":"4342_CR48","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1164\/rccm.202403-0636OC","volume":"210","author":"L Lancaster","year":"2024","unstructured":"Lancaster L, Cottin V, Ramaswamy M, Wuyts WA, Jenkins RG, Scholand MB, et al. Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial. Am J Respir Crit Care Med. 2024;210:424\u201334. https:\/\/doi.org\/10.1164\/rccm.202403-0636OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"4342_CR49","doi-asserted-by":"publisher","first-page":"2201794","DOI":"10.1183\/13993003.01794-2022","volume":"61","author":"IR Strambu","year":"2023","unstructured":"Strambu IR, Seemayer CA, Fagard LM-CA, Ford PA, Van Der Aa TAK, De Haas-Amatsaleh AA, et al. GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial. Eur Respir J. 2023;61:2201794. https:\/\/doi.org\/10.1183\/13993003.01794-2022.","journal-title":"Eur Respir J"},{"key":"4342_CR50","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1001\/jama.2023.5355","volume":"329","author":"TM Maher","year":"2023","unstructured":"Maher TM, Ford P, Brown KK, Costabel U, Cottin V, Danoff SK, et al. Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials. JAMA. 2023;329:1567. https:\/\/doi.org\/10.1001\/jama.2023.5355.","journal-title":"JAMA"},{"key":"4342_CR51","doi-asserted-by":"publisher","unstructured":"Xu Z, Wang P, Cao J, Tan C, Ma D, Zhao L, et al. INS018-055, A Novel Traf2- and NCK-interacting Kinase (TNIK) Inhibitor, Improves Lung Function in Patients With Idiopathic Pulmonary Fibrosis: Results From a Randomized, Double-blind, Placebo-controlled Phase 2a Study. https:\/\/doi.org\/10.1164\/ajrccm.2025.211.Abstracts.A2904.","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A2904"},{"key":"4342_CR52","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1164\/rccm.202112-2824OC","volume":"206","author":"G Raghu","year":"2022","unstructured":"Raghu G, Mouded M, Chambers DC, Martinez FJ, Richeldi L, Lancaster LH, et al. A Phase IIb Randomized Clinical Study of an Anti-\u03b1v \u03b26 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022;206:1128\u201339. https:\/\/doi.org\/10.1164\/rccm.202112-2824OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"4342_CR53","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1038\/s41591-025-03743-2","volume":"31","author":"Z Xu","year":"2025","unstructured":"Xu Z, Ren F, Wang P, Cao J, Tan C, Ma D, et al. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nat Med. 2025;31:2602\u201310. https:\/\/doi.org\/10.1038\/s41591-025-03743-2.","journal-title":"Nat Med"},{"key":"4342_CR54","doi-asserted-by":"publisher","first-page":"104481","DOI":"10.1016\/j.ebiom.2023.104481","volume":"90","author":"A Nambiar","year":"2023","unstructured":"Nambiar A, Kellogg D, Justice J, Goros M, Gelfond J, Pascual R, et al. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability. eBioMedicine. 2023;90:104481. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104481.","journal-title":"eBioMedicine"},{"key":"4342_CR55","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41587-024-02143-0","volume":"43","author":"F Ren","year":"2025","unstructured":"Ren F, Aliper A, Chen J, Zhao H, Rao S, Kuppe C, et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat Biotechnol. 2025;43:63\u201375. https:\/\/doi.org\/10.1038\/s41587-024-02143-0.","journal-title":"Nat Biotechnol"},{"key":"4342_CR56","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.4049\/jimmunol.171.10.5537","volume":"171","author":"D Pilling","year":"2003","unstructured":"Pilling D, Buckley CD, Salmon M, Gomer RH. Inhibition of Fibrocyte Differentiation by Serum Amyloid P. J Immunol. 2003;171:5537\u201346. https:\/\/doi.org\/10.4049\/jimmunol.171.10.5537.","journal-title":"J Immunol"},{"key":"4342_CR57","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1524-475X.2008.00366.x","volume":"16","author":"B Naik-Mathuria","year":"2008","unstructured":"Naik-Mathuria B, Pilling D, Crawford JR, Gay AN, Smith CW, Gomer RH, et al. Serum amyloid P inhibits dermal wound healing. Wound Repair Regen. 2008;16:266\u201373. https:\/\/doi.org\/10.1111\/j.1524-475X.2008.00366.x.","journal-title":"Wound Repair Regen"},{"key":"4342_CR58","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.biocel.2010.10.013","volume":"43","author":"LA Murray","year":"2011","unstructured":"Murray LA, Chen Q, Kramer MS, Hesson DP, Argentieri RL, Peng X, et al. TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. Int J Biochem Cell Biol. 2011;43:154\u201362. https:\/\/doi.org\/10.1016\/j.biocel.2010.10.013.","journal-title":"Int J Biochem Cell Biol"},{"key":"4342_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-025-01973-y","author":"D Lee","year":"2025","unstructured":"Lee D, Kong B, Kwak G, Kang B, Swaby C, Fanaroff R, et al. Clinically translatable anti-fibrotic nanosuspension for inhaled treatment of idiopathic pulmonary fibrosis. Drug Deliv Transl Res. 2025. https:\/\/doi.org\/10.1007\/s13346-025-01973-y.","journal-title":"Drug Deliv Transl Res"},{"key":"4342_CR60","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.7150\/thno.72269","volume":"12","author":"M Wang","year":"2022","unstructured":"Wang M, Liu A-D, Niu Q, Feng X, Zheng Y-Y, Chen S-J, et al. Blockade of phosphotyrosine pathways suggesting SH2 superbinder as a novel therapy for pulmonary fibrosis. Theranostics. 2022;12:4513\u201335. https:\/\/doi.org\/10.7150\/thno.72269.","journal-title":"Theranostics"},{"key":"4342_CR61","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40265-021-01487-0","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb YN, Nintedanib. A Review in Fibrotic Interstitial Lung Diseases. Drugs. 2021;81:575\u201386. https:\/\/doi.org\/10.1007\/s40265-021-01487-0.","journal-title":"Drugs"},{"key":"4342_CR62","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jare.2022.10.018","volume":"51","author":"C Gan","year":"2023","unstructured":"Gan C, Wang Y, Xiang Z, Liu H, Tan Z, Xie Y, et al. Niclosamide-loaded nanoparticles (Ncl-NPs) reverse pulmonary fibrosis in vivo and in vitro. J Adv Res. 2023;51:109\u201320. https:\/\/doi.org\/10.1016\/j.jare.2022.10.018.","journal-title":"J Adv Res"},{"key":"4342_CR63","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/resp.14452","volume":"28","author":"Y Inoue","year":"2023","unstructured":"Inoue Y, Wells AU, Song JW, Xu Z, Kitamura H, Suda T, et al. Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial. Respirology. 2023;28:465\u201374. https:\/\/doi.org\/10.1111\/resp.14452.","journal-title":"Respirology"},{"key":"4342_CR64","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/resp.14116","volume":"26","author":"MT Durheim","year":"2021","unstructured":"Durheim MT, Bendstrup E, Carlson L, Sutinen EM, Hyldgaard C, Kalafatis D, et al. Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort. Respirology. 2021;26:982\u20138. https:\/\/doi.org\/10.1111\/resp.14116.","journal-title":"Respirology"},{"key":"4342_CR65","doi-asserted-by":"publisher","unstructured":"Seeliger B, Ruwisch J, B\u00fclow Sand JM, Sim\u00f5es FB, Jessen H, Boerner E, et al. Differential Effects of Antifibrotic Treatment on Outcome Prediction via Serial Matrix Metalloproteinase-Degraded C-Reactive Protein Neoepitope Levels in Idiopathic Pulmonary Fibrosis. Chest. 2025;S0012369225053942. https:\/\/doi.org\/10.1016\/j.chest.2025.08.047.","DOI":"10.1016\/j.chest.2025.08.047"},{"key":"4342_CR66","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12890-024-02861-w","volume":"24","author":"X Wu","year":"2024","unstructured":"Wu X, Li W, Luo Z, Chen Y. A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials. BMC Pulm Med. 2024;24:58. https:\/\/doi.org\/10.1186\/s12890-024-02861-w.","journal-title":"BMC Pulm Med"},{"key":"4342_CR67","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00228-024-03720-7","volume":"80","author":"M Kou","year":"2024","unstructured":"Kou M, Jiao Y, Li Z, Wei B, Li Y, Cai Y, et al. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2024;80:1445\u201360. https:\/\/doi.org\/10.1007\/s00228-024-03720-7.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04342-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04342-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04342-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:32:01Z","timestamp":1783045921000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04342-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4342"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04342-8","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a network meta-analysis of published randomized controlled trials (RCTs). Ethical approval and informed consent were obtained by the original studies included in this analysis. The authors confirm that all methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"294"}}